AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04485767 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training Exercise
Description: Progressive Resistance Training Exercise 2x weekly for 6 months.
Study NCT04485767 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility and Balance Exercise
Description: Flexibility and Balance Exercise Training Exercise 2x weekly for 6 months.
Study NCT00777972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
Study NCT01403077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 480 Biomedical Bioresorbable Scaffold System
Description: 480 Biomedical Bioresorbable Scaffold System
Study NCT02265380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placement of IV catheter
Study NCT02265380 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of IV catheter
Study NCT00075569 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HspE7
Description: 500 micrograms of SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked to the entire sequence of HPV 16 E7.
Study NCT02862847 — intervention group
Intervention type: OTHER
Intervention: stool samples
Study NCT03684187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Intervention
Description: Mindfulness - Based Intervention (MBI) Course:~The 8-week MBI program is comprised of an orientation session, 8 separate weekly sessions of 2.5 hours and also a 7.5 hour retreat session on a weekend day. The orientation session will include an introductory session, description of the course and will include completion of stress surveys. During the orientation session, there will be explanation to the patients of objectively the basis of mindfulness teaching. The role of the stress surveys that are conducted are to assess an individual's degree of stress prior to the initiation of any mindfulness practice teaching.~Subjects will also be asked to wear a BodyGuard 2 (BG2) for parts of the study, on average of 7 days at baseline, end of the control phase, end of intervention phase, and end of 48 week follow up period. This will track subjects heart rate (HR), HR variability, VO2, energy expenditure and activity.
Study NCT01084590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating/Physical Activity
Description: This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
Study NCT01084590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety/Injury Prevention
Description: This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
Study NCT02971059 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phenylalanine intake
Description: Phenylalanine will be provided as graded intakes ranging from 7-40 mg/kg/day
Study NCT01099345 — intervention group
Intervention type: PROCEDURE
Intervention: cystometry (CMG)
Description: recording device measuring pressures though catheters placed in bladder and rectum
Study NCT01099345 — intervention group
Intervention type: PROCEDURE
Intervention: polysomnography (PSG)
Description: Recording device measuring sleep activity through electrodes attached to the subject
Study NCT01001585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached, which will take approximately 10 minutes.
Study NCT03855072 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: customized fixation plate
Description: * All cases will undergo one surgery under general anesthesia.~* Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~* Amucoperiosteal flap was reflected to expose the lateral mandibular ramus to the posterior border and the sigmoid notch~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* 3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~* The customized fixation plate is positioned to fix the proximal and distal segment together after setback
Study NCT03855072 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maxillomandibular fixation
Description: * All cases will undergo one surgery under general anesthesia.~* incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~* The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~* Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint to assure accuracy of the mandibular position.
Study NCT04642144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yerba mate infusion
Description: Yerba mate infusion intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of the infusion right before the exercise protocol test, without consumption of a carbohydrate-based meal, keeping the individual fasted.~Yerba mate and carbohydrate intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of a meal based on carbohydrate right before the exercise protocol test with another infusion of yerba mate.
Study NCT04642144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yerba mate infusion
Description: Yerba mate infusion intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of the infusion right before the exercise protocol test, without consumption of a carbohydrate-based meal, keeping the individual fasted.~Yerba mate and carbohydrate intervention is characterized by the consumption of the infusion of yerba mate for 7 days preceding the test, with consumption of a meal based on carbohydrate right before the exercise protocol test with another infusion of yerba mate.
Study NCT04642144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate meal
Description: Carbohydrate meal intervention is characterized by the consumption of a carbohydrate-based meal right before the exercise protocol test, without consumption yerba mate infusion.
Study NCT04642144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate meal
Description: Carbohydrate meal intervention is characterized by the consumption of a carbohydrate-based meal right before the exercise protocol test, without consumption yerba mate infusion.
Study NCT03369847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide, beclomethasone
Description: The inhaled corticosteroids we are using for this study are budesonide nebulized solution and beclomethasone metered-dose inhaler. Low-doses for these medications are 0.5mg/day for budesonide and 160 mcg/day for beclomethasone. Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer. Budesonide is FDA approved for children under 5 years of age. Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer. Beclomethasone is FDA approved for children 5 years and older.
Study NCT02591992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac CT as the first diagnostic modality in suspected CAD
Description: Performation of non-invasive cardiac CT angiogram
Study NCT02591992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invasive coronary angiography as indicated by the guidelines
Description: Patient undergoes invasive coronary angiography
Study NCT02688569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Chronic Widespread Pain
Description: CBT-CWP in this study involves 4 sessions of one-hour non-drug behavioral intervention. Session 1 involves education about pain and insomnia and the relationship between the two. Participants will also learn sleep hygiene and stimulus control skills. Session 3 involves teaching participants skills to limit non-sleep time in bed and thus increase sleep efficiency. Participants will also learn the relationship between pain and activity. Session 4 involves teaching participants cognitive restructuring and mindfulness skills to manage maladaptive thoughts related to pain and insomnia. Participants will also review the skills they learned and discuss the maintenance of treatment gains.
Study NCT01106261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Description: Pulmonary Metastasectomy
Study NCT01106261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active monitoring
Description: Active monitoring
Study NCT01023529 — intervention group
Intervention type: RADIATION
Intervention: Palliative pelvic soft-tissue radiation (external beam)
Description: 3 Gy x 10-13 (range 30 - 39 Gy total)
Study NCT04527757 — intervention group
Intervention type: PROCEDURE
Intervention: Inhalation induction
Description: For the inhalation induction sevoflurane will be used (in the mixture with O2 + air, or O2 + N2O).
Study NCT04527757 — intervention group
Intervention type: PROCEDURE
Intervention: Intravenous induction
Description: For the intravenous induction, commonly used induction anaesthetics will be used (propofol, etomidate, ketamine, midazolam).
Study NCT03941548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Administered as 12 mg tablets.
Study NCT03941548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543 Matching Placebo
Description: Administered as tablets to aid treatment masking.
Study NCT00658229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training group
Description: After 5-10 months on androgen deprivation therapy the patients in the intervention group go through a four months strength training intervention. The patients will perform three strength-training sessions per week, two under supervision of a sport instructor. Each session will consists of one-three sets of nine strength-training exercises, performed at an intensity of 6 or 10 repetitions of maximum (6-10 RM).
Study NCT03663244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Standardised stress reduction programme with established efficacy
Study NCT03663244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LSR
Description: Existing stress reduction programme in a Danish municipality
Study NCT01389128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-pharmacological resources
Description: A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~* Pelvic mobility on the exercise ball oriented and accompanied by the researcher for 40 minutes;~* Lumbosacral massage for a period of 40 minutes, when dilation was between 5 and 6 cm. During the procedure, the woman in labor was allowed to freely choose the most comfortable position; and,~* Warm shower with the water flow directed to the lower-back of the woman in labor, for 40 minutes, when uterine cervical dilation was equal to or higher than 7cm.
Study NCT01389128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
Study NCT03795350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide
Description: single inhalation of 99mTc radiolabelled TRIMBOW pMDI (4 puffs for a total dose of 400mcg BDP, 24mcg FF, 50 mcg GB)
Study NCT01655511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 240 mg, solution, single dose
Study NCT01655511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 480 mg, solution, single dose
Study NCT01655511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: TBD dose will be a single dose if \< 720 mg or a loading dose followed by additional dose if > 720 mg.
Study NCT02305433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based physiotherapy (physical exercise)
Description: Each physiotherapy (physical exercise) session includes muscle strength and endurance training (especially for lower limbs), balance and coordination training and functional training. Functional training includes walking exercises and ADL (activities of daily living) exercises. In addition the physiotherapist gives counseling on nutrition.
Study NCT01521845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega 3
Description: 3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
Study NCT00777972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
Study NCT03679598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvelestat (MPH966)
Description: Alvelestat was developed as treatment for lung diseases like Chronic Obstructive Pulmonary Disease. Alevelestat works by blocking certain proteins in the body that are responsible for inflammation and damage to the lungs that can lead to COPD symptoms.
Study NCT03679598 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a pill or tablet that does not contain any study drug.
Study NCT01015703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoVaccine HT
Description: intramuscular injection, dose escalation
Study NCT04550702 — intervention group
Intervention type: DRUG
Intervention: Mirabegron 25mg
Description: Mirabegron 25 mg per day
Study NCT01639911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.
Study NCT01639911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib at the assigned dose once a day continuously for the duration of treatment.
Study NCT03182075 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Training
Description: OCD and hoarding disorder participants will receive 14 sessions of training via computer within 3 weeks.
Study NCT03182075 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computerized Training
Description: OCD and hoarding disorder participants will receive 14 sessions of training via computer within 3 weeks.
Study NCT01711632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle for research purposes only. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Following the third cycle assessments, patients who achieve complete response (CR) with detectable MRD or partial response (PR) may continue with vemurafenib for up to 3 additional cycles at the treating physician's discretion (Cycles 4-6). Patients who achieve CR without MRD will be observed as part of post-treatment followup, and may be re-treated with vemurafenib after relapse (as per below). Patients who achieve no response (NR) after the initial 3 cycles of vemurafenib will be removed from the study. They will be followed every 3 months as part of posttreatment followup for a total of 12 months.
Study NCT04267614 — intervention group
Intervention type: DRUG
Intervention: Etanercept
Description: Patients who received etanercept for RA
Study NCT01763957 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training (PFMT)
Description: All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list .
Study NCT03024164 — intervention group
Intervention type: OTHER
Intervention: Treatment following current guidelines
Description: Treatment following current guidelines
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study NCT02465060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT02465060 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given IV
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Give PO
Study NCT02465060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT01654822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical application cervical spray
Description: one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
Study NCT01654822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical spray on the cervix
Description: one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix
Study NCT04074759 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FPT155
Description: A soluble CD80 fusion protein
Study NCT04074759 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: An anti-PD1 antibody
Study NCT05995821 — intervention group
Intervention type: OTHER
Intervention: Collection of biological specimens
Description: Collection of tumor, blood, lymph nodes, white blood cells, mouth cells (buccal smears) scraped from the inside of your cheek, urine, saliva, or other tissue samples.
Study NCT03412396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study NCT03412396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03412396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo radical prostatectomy
Study NCT02578368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2600 mg/m², d1 i.v., every 2 weeks
Study NCT02578368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 2600 mg/m², d1 i.v., every 2 weeks
Study NCT02578368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m², d1, i.v., every 2 weeks
Study NCT02578368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: 200 mg/m², d1, i.v., every 2 weeks
Study NCT03465956 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Laparoscopic Sleeve Gastrectomy using the gastro-intestinal anastomosis stapler.
Study NCT05164328 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02454114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HOMEFIRST
Description: HOMEFIRST patients receive monitoring and review of; vital signs, symptoms, mental state, nutrition and hydration, urine output, skin turgor and integrity, mobility, coping ability, medication concordance, smoking and nutrition and hydration. Individualised verbal and written self-management plans, a list of symptoms (including red flag symptoms) to prompt contact with the study team and a 24hr emergency contact number are provided. Clinical bloods and other investigations will be taken/requested as necessary. Questionnaires will be completed as follows; SF-12 - at recruitment and 6 weeks, CAP-SYM - at recruitment and 6 weeks. Satisfaction questionnaires are conducted over the telephone at 2 wks by an independent assessor. As part of usual clinical practice patients will have bloods and radiology requested as required.
Study NCT02454114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Hospital Care
Description: No research investigations will occur except for questionnaires; as part of usual clinical practice patients will have bloods and radiology requested as desired by their usual clinical team.~SF-12 (physical and mental function) \[performed twice in total\] - at recruitment (day 0) and 6 weeks~CAP-SYM \[performed 3 times in total\] - at recruitment day 0 (twice including day minus 30) and 6 weeks~Patient (and carer/consultee) satisfaction - conducted over the telephone at 2 wks by an independent assessor.